Triple antithrombotic therapy (oral anticoagulation, aspirin, and clopidogrel) is commonly used after coronary stenting in patients with atrial fibrillation. However, the optimal duration of triple therapy is unclear due to the risk of bleeding. This study reviewed the current evidence and guidelines to develop recommendations on the duration of triple antithrombotic therapy based on patient's stroke risk and type of stent placed. For patients at moderate to high risk of stroke, triple therapy for 1 month after a bare-metal stent or 6 months after a drug-eluting stent is recommended, followed by dual antiplatelet therapy or oral anticoagulation alone depending on the individual patient's risks.